http://iii/investment/detail?code=cotn:RENE.L&display=news http://www.iii.co.uk/investment/detail?code=cotn:RENE.L&display=news&action=article&articleid=7798570&from=rss LONDON, March 18 (Reuters) - ReNeuron Group Plc: * Signs further stem cell manufacturing contracts * Contracts with angel biotechnology for stroke clinical trial ((London Equities Newsroom; +44 20 7542 7717)) (For more news, please click here) COPYRIGHT Copyright Thomson Reuters 2010.... Thu, 18 Mar 2010 07:26:00 GMT http://www.iii.co.uk/investment/detail?code=cotn:RENE.L&display=news&action=article&articleid=7798426&from=rss RNS Number : 7602I ReNeuron Group plc 18 March 2010 PRESS RELEASE ReNeuron signs further stem cell manufacturing contracts with Angel Biotechnology for stroke clinical trial Guildford, UK, 18 March 2010: ReNeuron Group plc (LSE: RENE.L) today announces that it has signed two further clinical-grade... Thu, 18 Mar 2010 07:02:00 GMT http://www.iii.co.uk/investment/detail?code=cotn:RENE.L&display=news&action=article&articleid=7792641&from=rss RNS Number : 5917I ReNeuron Group plc 15 March 2010 SECOND CLOSING OF THE PLACING Guildford, UK, 15 March 2010: ReNeuron Group plc (LSE: RENE.L) announced on 22 February 2010 that it had raised approximately £4.7 million, before expenses, from existing and new institutional and qualifying individual... Mon, 15 Mar 2010 14:44:00 GMT http://www.iii.co.uk/investment/detail?code=cotn:RENE.L&display=news&action=article&articleid=7790008&from=rss RNS Number : 5135I ReNeuron Group plc 12 March 2010 RESULT OF GENERAL MEETING AND FIRST CLOSING OF THE PLACING Guildford, UK, 12 March 2010: ReNeuron Group plc (LSE: RENE.L) announced on 22 February 2010 that it had raised approximately £4.7 million, before expenses, from existing and new... Fri, 12 Mar 2010 12:18:00 GMT http://www.iii.co.uk/investment/detail?code=cotn:RENE.L&display=news&action=article&articleid=7773863&from=rss LONDON, March 3 (Reuters) - ReNeuron Group Plc: * Positive pre-clinical mouse efficacy data with REN009 stem cell therapy for peripheral arterial disease (PAD) in diabetes * Applications to commence initial clinical trials planned for next year ((London Equities Newsroom; +44 20 7542 7717))... Wed, 03 Mar 2010 07:21:00 GMT http://www.iii.co.uk/investment/detail?code=cotn:RENE.L&display=news&action=article&articleid=7773711&from=rss RNS Number : 9838H ReNeuron Group plc 03 March 2010 PRESS RELEASE ReNeuron presents key pre-clinical efficacy data with ReN009 stem cell therapy at leading UK diabetes conference Break-through in the potential restorative treatment of peripheral arterial disease in diabetic patients Guildford,... Wed, 03 Mar 2010 07:02:00 GMT http://www.iii.co.uk/investment/detail?code=cotn:RENE.L&display=news&action=article&articleid=7758558&from=rss RNS Number : 4487H ReNeuron Group plc 22 February 2010 PRESS RELEASE ReNeuron announces fundraising Guildford, UK, 22 February 2010: ReNeuron Group plc (LSE: RENE.L) today announces that it has raised approximately £4.7 million, before expenses, from existing and new institutional and qualifying... Mon, 22 Feb 2010 07:03:00 GMT http://www.iii.co.uk/investment/detail?code=cotn:RENE.L&display=news&action=article&articleid=7754938&from=rss RNS Number : 3142H ReNeuron Group plc 18 February 2010 PRESS RELEASE ReNeuron and Schepens Eye Research Institute receive unrestricted industrial grant to support US retinal stem cell collaboration Guildford, UK, 18 February 2010: ReNeuron Group plc (LSE: RENE.L) today announces that its ongoing... Thu, 18 Feb 2010 07:00:00 GMT http://www.iii.co.uk/investment/detail?code=cotn:RENE.L&display=news&action=article&articleid=7744758&from=rss By Ben Hirschler LONDON, Feb 10 (Reuters) - British biotech company ReNeuron and a team of doctors in Scotland have won final approval to start a pioneering clinical trial to assess whether stem cell therapy can help patients disabled by stroke. The treatment involves injecting neural stem... Wed, 10 Feb 2010 09:13:00 GMT http://www.iii.co.uk/investment/detail?code=cotn:RENE.L&display=news&action=article&articleid=7744554&from=rss By Ben Hirschler LONDON, Feb 10 (Reuters) - British biotech company ReNeuron and a team of doctors in Scotland have won final approval to start a pioneering clinical trial to assess whether stem cell therapy can help patients disabled by stroke. The treatment involves injecting neural stem... Wed, 10 Feb 2010 07:15:00 GMT http://www.iii.co.uk/investment/detail?code=cotn:RENE.L&display=news&action=article&articleid=7744453&from=rss RNS Number : 9220G ReNeuron Group plc 10 February 2010 PRESS RELEASE ReNeuron receives final regulatory approval to commence landmark stroke clinical trial in UK Guildford, UK, 10 February 2010: ReNeuron Group plc (LSE: RENE.L) today announces that the UK Gene Therapy Advisory Committee (GTAC)... Wed, 10 Feb 2010 07:03:00 GMT http://www.iii.co.uk/investment/detail?code=cotn:RENE.L&display=news&action=article&articleid=7741563&from=rss RNS Number : 8226G ReNeuron Group plc 08 February 2010 8 February 2010 ReNeuron Group plc ISSUE OF ORDINARY SHARES ReNeuron Group plc (LSE: RENE.L: "the Company") today announces that, pursuant to the terms of the Flexible Use Small Capital Increase Agreement ("FUSCIA") entered into with... Mon, 08 Feb 2010 12:55:00 GMT http://www.iii.co.uk/investment/detail?code=cotn:RENE.L&display=news&action=article&articleid=7731026&from=rss RNS Number : 4130G ReNeuron Group plc 01 February 2010 PRESS RELEASE Clinical Advisory Board appointments Guildford, UK, 1 February 2010: ReNeuron Group plc (LSE: RENE.L) today announces the appointment of four opinion-leading clinicians to its newly-established Clinical Advisory Board for... Mon, 01 Feb 2010 07:05:00 GMT http://www.iii.co.uk/investment/detail?code=cotn:RENE.L&display=news&action=article&articleid=7726722&from=rss RNS Number : 2453G ReNeuron Group plc 28 January 2010 PRESS RELEASE Regulatory update Guildford, UK, 28 January 2010: ReNeuron Group plc (LSE: RENE.L) today provides a regulatory update regarding its ReN001 stem cell therapy for stroke. On 11 January, the Company announced that it had finalised... Thu, 28 Jan 2010 07:01:00 GMT http://www.iii.co.uk/investment/detail?code=cotn:RENE.L&display=news&action=article&articleid=7726299&from=rss By Maggie Fox, Health and Science Editor WASHINGTON, Jan 27 (Reuters) - Using just three genes, California researchers have transformed mouse skin cells directly into nerve cells called neurons. Here are some questions and answers about the field and about this experiment by a team from Stanford... Wed, 27 Jan 2010 19:44:00 GMT http://www.iii.co.uk/investment/detail?code=cotn:RENE.L&display=news&action=article&articleid=7726240&from=rss Jan 27 (Reuters) - U.S. researchers said on Wednesday they had transformed ordinary mouse skin cells directly into nerve cells in an experiment bypassing the stem cell stage. Scientists had been working to transform cells into stem cells first to accomplish this and a whole industry has arisen... Wed, 27 Jan 2010 18:15:00 GMT http://www.iii.co.uk/investment/detail?code=cotn:RENE.L&display=news&action=article&articleid=7725373&from=rss RNS Number : 2000G ReNeuron Group plc 27 January 2010 PRESS RELEASE ReNeuron welcomes launch of Office for Life Sciences "Life Sciences 2010" report Guildford, UK, 27 January 2010: ReNeuron Group plc (LSE: RENE.L) welcomes yesterday's launch of the "Life Sciences 2010: Delivering the Blueprint"... Wed, 27 Jan 2010 11:42:00 GMT http://www.iii.co.uk/investment/detail?code=cotn:RENE.L&display=news&action=article&articleid=7699275&from=rss RNS Number : 3019F ReNeuron Group plc 11 January 2010 PRESS RELEASE Regulatory update Guildford, UK, 11 January 2010: ReNeuron Group plc (LSE: RENE.L) today provides a regulatory update regarding its ReN001 stem cell therapy for stroke and its ReN009 stem cell therapy for peripheral arterial... Mon, 11 Jan 2010 07:01:00 GMT